Avoid Parabolic Drugs: Satish Betadpur, Independent International Investment Research PLC

Satish Betadpur, CFA, Global Research Director, Independent International Investment Research PLC, in a chat with ET Now talks about Parabolic Drugs.

Satish Betadpur, CFA, Global Research Director, Independent International Investment Research PLC, in a chat with ET Now talks about Parabolic Drugs.

Is it probably worth entering into Parabolic Drugs or should one just stay off?

It is better to stay away from this. There are better counters than the entire drug space. We really like healthcare but as far as this particular one is concerned, there was no real competitive advantage for this. They really does not touch the radar of FIIs that we service. So it was not something that we did a lot of analysis on. But on just some basic calculation, we found this stock to be overvalued, not really something that we would look into at this point either.
ADVERTISEMENT
READ MORE

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Markets › Stocks › Recos › Avoid Parabolic Drugs: Satish Betadpur, Independent International Investment Research PLC
Text Size:AAA
Success
This article has been saved

*

+